European respiratory drug market was $11.1 billion in 2018 and is anticipated to grow at a substantial rate of 7.0% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in Europe. Major countries that will contribute to the respiratory drug market within the region includes UK, Germany, France, Italy and Spain. A significant number of companies, research, patient base has been observed in the market due to which a significant growth can be observed in the market. According to the International Monetary Fund (IMF), Europe is home to around 740 million people and the GDP of the European Union was $19.7 trillion in 2017. As per Organization for Economic Co-operation and Development (OECD), the self-reported asthma rate and COPD rate by European Union countries were 6.1% and 4.0% respectively and it has been found out that the rate of prevalence of diseases are higher in women as compared to men. This is expected to drive the regional business growth of the respiratory drug market.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/european-respiratory-drug-market
The European respiratory drug market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the economies of the region such as UK, Germany, France, and others. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/european-respiratory-drug-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drug to cater to a wide range of customers within and outside the region. The major players of the European respiratory drug market include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Market Segmentation
European Respiratory Drug Market by Route of Administration
- Oral
- Injectable
- Inhalable
European Respiratory Drug Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
European Respiratory Drug Market by End-User
- Homecare
- Hospitals and Clinics
Regional Analysis
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Company Profiles
- Air Liquide S.A.
- Aradigm Corp.
- AstraZeneca PLC
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- Merck & Co.
- Novartis AG
- Omron Healthcare Inc.
- Pfizer Inc.
- Pulmatrix Inc.
- ResMed Corp.
- Savara, Inc.
- Sunovion Pharmaceuticals
- Takeda Pharmaceutical Company Ltd.
- Teva Pharmaceuticals Industries Ltd.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-respiratory-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
